TBI 1301

Drug Profile

TBI 1301

Alternative Names: NY-ESO-1 antigen-specific RetroNectin® TCR gene therapy - Takara Bio; NY-ESO-1 antigen-specific TCR-gene-transduced autologous lymphocytes - Takara Bio; NY-ESO-1 siTCR gene therapy; TBI-1301; TBI-1301A

Latest Information Update: 28 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Takara Bio
  • Developer Fred Hutchinson Cancer Research Center; Mie University; National Cancer Institute (USA); Takara Bio; University Health Network
  • Class Gene therapies; T lymphocyte cell therapies
  • Mechanism of Action Gene transference; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Malignant melanoma
  • Phase I/II Synovial sarcoma
  • Phase I Solid tumours; T cell lymphoma
  • No development reported Sarcoma

Most Recent Events

  • 28 Feb 2018 No recent reports of development identified for phase-I development in Sarcoma in USA (IV)
  • 09 Dec 2017 Efficacy and adverse events data from a phase I trial in Synovial sarcoma presented at the 59th Annual Meeting and Exposition of the American Society of Haematology (ASH-2017)
  • 01 Dec 2017 Phase-I clinical trials in T-cell lymphoma (Second-line therapy or greater) in Japan (IV) (JapicCTI183830)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top